Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF

Abstract

Background and Aims As a hepatocellular carcinoma biomarker, serum Golgi protein 73 (GP73) is reportedly related to inflammation. Acute-on-chronic liver failure (ACLF) is characterized by severe systemic inflammation. In this study, we aimed to explore the association between the GP73 level and short-term mortality in patients with alcohol-associated liver disease-related ACLF (ALD-ACLF). Methods This retrospective cohort study involved 126 Chinese adults with ALD-ACLF. Baseline serum GP73 level was measured using enzyme-linked immunosorbent assay. Patients were followed-up for 90 d and outcomes were assessed. Data were analyzed using multivariate Cox regression and piecewise linear regression analyses. The predictive value of GP73 and classic models for the short-term prognosis of participants were evaluated and compared using receiver operating characteristic curves. Results The serum GP73 level was independently associated with an increased mortality risk in patients with ALD-ACLF. Compared with the lowest tertile, the highest serum GP73 level predisposed patients with ALD-ACLF to a higher mortality risk in the fully adjusted model [at 28 days: hazard ratio (HR): 4.29 (0.99–18.54), p =0.0511; at 90 days: HR: 3.52 (1.15–10.79), p =0.0276]. Further analysis revealed a positive linear association. GP73 significantly improved the accuracy of the Child-Turcotte-Pugh score, model for end-stage liver disease score, and model for end-stage liver disease-sodium score in predicting short-time prognosis of patients with ALD-ACLF. Conclusions The serum GP73 level is a significant predictor of the subsequent risk of death in patients with ALD-ACLF. GP73 improved the predictive value of classic prognostic scores.

ETS2 alleviates acute‐on‐chronic liver failure by suppressing excessive inflammation

“…ETS2 is expressed in a variety of cell types (endothelial cells, macrophages, and stromal fibroblasts) and has been implicated in various diseases, such as atherosclerosis, diabetes mellitus, and the cecal ligation and Although there are many biomarkers for the prognosis of ACLF, the discovery of these molecules has mostly been based on clinical laboratory indicators, which do not reflect the complex backgrounds of diseases. [22][23][24][25] However, the current study was based on a multigroup comparison using transcriptomics, which is more rigorous in terms of methods. Compared to histological biopsy, the use of ETS2 as a noninvasive single biomarker to distinguish the prognosis of ACLF patients is simple and practical.…”

“…Although there are many biomarkers for the prognosis of ACLF, the discovery of these molecules has mostly been based on clinical laboratory indicators, which do not reflect the complex backgrounds of diseases 22–25 . However, the current study was based on a multigroup comparison using transcriptomics, which is more rigorous in terms of methods.…”